2-chloromethyl-1,4,5,6-tetrahydro-pyrimidine hydrochloride | 79983-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloromethyl-1,4,5,6-tetrahydro-pyrimidine hydrochloride
• 英文别名: 2-Chlormethyl-1,4,5,6-tetrahydro-pyrimidin; Hydrochlorid；2-(Chloromethyl)-1,4,5,6-tetrahydropyrimidine hydrochloride；2-(chloromethyl)-1,4,5,6-tetrahydropyrimidine;hydrochloride
• CAS: 79983-34-9
• 化学式: C₅H₉ClN₂*ClH
• 分子量: 169.054
• InChiKey: HZQPQQYMQHZSMO-UHFFFAOYSA-N

物化性质

• 熔点：
  224-225 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  24.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloromethyl-1,4,5,6-tetrahydro-pyrimidine hydrochloride 、 2-amino-9H-pyrido[2,3-b]indole-3-carboxamide 在 氢氧化钾 作用下， 以 二甲基亚砜 为溶剂， 反应 0.17h， 以10%的产率得到2-amino-9-(1,4,5,6-tetrahydropyrimidin-2-ylmethyl)-9H-pyrido[2,3-b]indole-3-carboxamide
  参考文献：
  名称：

  Alpha carbolines and uses thereof

  摘要：

  这项发明提供了式I的α-咔啉化合物： 其中R1、R2、R3、R4、R5和x如规范中所述。这些化合物可用于治疗炎症性疾病和癌症。

  公开号：

  US20070207997A1
• 作为产物：
  描述：

  1,3-丙二胺 、 2-Chloroethanimine 在 N,N-二异丙基乙胺 、 盐酸 作用下， 以 乙醇 、 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 2-chloromethyl-1,4,5,6-tetrahydro-pyrimidine hydrochloride
  参考文献：
  名称：

  5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS

  摘要：

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。

  公开号：

  US20070105866A1

文献信息

• [EN] REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR<br/>[FR] RÉDUCTION DE HDL PRO-INFLAMMATOIRE À L'AIDE D'UN INHIBITEUR DE LEUCOTRIÈNE
  申请人：AUTOIMMUNE PHARMA LLC

  公开号：WO2018152405A1

  公开（公告）日：2018-08-23

  A method involving the administration of a therapeutically effective amount of a leukotriene inhibitor, a pharmaceutically acceptable salt, a pharmaceutically acceptable N-oxide, a pharmaceutically active metabolite, a pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof to a human for reducing a level of pro-inflammatory HDL in the human. Various examples of leukotriene inhibitors, including 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin- 3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2, 2-dimethyl-propionic acid, are disclosed for administration for the reduction of pro-inflammatory HDL in a human. Reduction of pro-inflammatory HDL by the leukotriene inhibitor may include conversion of at least a portion of pro-inflammatory HDL to anti-inflammatory HDL.

  一种方法，涉及给人类施用治疗有效量的白细胞三烯抑制剂、药物可接受的盐、药物可接受的N-氧化物、药物活性代谢物、药物可接受的的前药或其药物可接受的溶剂化物，以降低人类中的前炎症高密度脂蛋白(HDL)水平。公开了各种白细胞三烯抑制剂，包括3-[3-叔丁基硫基-1-[4-(6-乙氧基-吡啶-3-基)-苄基]-5-(5-甲基-吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸，用于施用以降低人类中的前炎症HDL。通过白细胞三烯抑制剂降低前炎症HDL可能包括将至少部分前炎症HDL转化为抗炎症HDL。
• 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
  申请人：Hutchinson John H.

  公开号：US20090221574A1

  公开（公告）日：2009-09-03

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了包含这些化合物的药物组合物，这些化合物调节5-脂氧合酶活化蛋白（FLAP）的活性。本文还描述了使用这样的FLAP调节剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或病症。
• ALPHA CARBOLINES AND USES THEREOF
  申请人：Hepperle Michael E.

  公开号：US20100311715A1

  公开（公告）日：2010-12-09

  This invention provides alpha-carboline compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and x are as described in the specification. The compounds are useful for treating inflammatory diseases and cancer.

  本发明提供了式I的α-咔啉化合物：其中R1，R2，R3，R4，R5和x如规范所述。该化合物可用于治疗炎症性疾病和癌症。
• 5-lipoxygenase-activating protein (FLAP) inhibitors
  申请人：Amira Pharmaceuticals, Inc.

  公开号：EP2404904A1

  公开（公告）日：2012-01-11

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了调节 5-脂氧合酶激活蛋白（FLAP）活性的化合物和含有此类化合物的药物组合物。本文还描述了使用此类 FLAP 调节剂（单独使用或与其他化合物结合使用）治疗呼吸系统、心血管和其他白三烯依赖性或白三烯介导的病症或疾病的方法。
• Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor
  申请人：Autoimmune Pharma LLC

  公开号：US20200147064A1

  公开（公告）日：2020-05-14

  A method involving the administration of a therapeutically effective amount of a leukotriene inhibitor, a pharmaceutically acceptable salt, a pharmaceutically acceptable N-oxide, a pharmaceutically active metabolite, a pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof to a human for reducing a level of pro-inflammatory HDL in the human. Various examples of leukotriene inhibitors, including 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, are disclosed for administration for the reduction of pro-inflammatory HDL in a human. Reduction of pro-inflammatory HDL by the leukotriene inhibitor may include conversion of at least a portion of pro-inflammatory HDL to anti-inflammatory HDL.